Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer
Taxanes are mainstay treatment of triple negative breast cancer (TNBC) patients but resistance often develops. Using TNBC patient-derived orthoxenografts (PDX) we have recently discovered that a CD49f+ chemoresistant population with tumor-initiating ability is present in sensitive tumors and expands...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-07-01
|
| Series: | Molecular & Cellular Oncology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/23723556.2017.1338208 |
| _version_ | 1797677229082148864 |
|---|---|
| author | Jorge Gomez-Miragaya Eva González-Suárez |
| author_facet | Jorge Gomez-Miragaya Eva González-Suárez |
| author_sort | Jorge Gomez-Miragaya |
| collection | DOAJ |
| description | Taxanes are mainstay treatment of triple negative breast cancer (TNBC) patients but resistance often develops. Using TNBC patient-derived orthoxenografts (PDX) we have recently discovered that a CD49f+ chemoresistant population with tumor-initiating ability is present in sensitive tumors and expands in tumors that have acquired resistance. Importantly, sensitivity to taxanes is recovered after long-term drug interruption. The characterization of this chemoresistant CD49f+ cells provides a unique opportunity to identify novel targets for the treatment of chemoresistant TNBC. |
| first_indexed | 2024-03-11T22:40:59Z |
| format | Article |
| id | doaj.art-9e0925ec87ed44fc950be5c6d32eb2bb |
| institution | Directory Open Access Journal |
| issn | 2372-3556 |
| language | English |
| last_indexed | 2024-03-11T22:40:59Z |
| publishDate | 2017-07-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Molecular & Cellular Oncology |
| spelling | doaj.art-9e0925ec87ed44fc950be5c6d32eb2bb2023-09-22T09:10:58ZengTaylor & Francis GroupMolecular & Cellular Oncology2372-35562017-07-014410.1080/23723556.2017.13382081338208Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancerJorge Gomez-Miragaya0Eva González-Suárez1Biomedical Research Institute of Bellvitge (IDIBELL)Biomedical Research Institute of Bellvitge (IDIBELL)Taxanes are mainstay treatment of triple negative breast cancer (TNBC) patients but resistance often develops. Using TNBC patient-derived orthoxenografts (PDX) we have recently discovered that a CD49f+ chemoresistant population with tumor-initiating ability is present in sensitive tumors and expands in tumors that have acquired resistance. Importantly, sensitivity to taxanes is recovered after long-term drug interruption. The characterization of this chemoresistant CD49f+ cells provides a unique opportunity to identify novel targets for the treatment of chemoresistant TNBC.http://dx.doi.org/10.1080/23723556.2017.1338208cd49f tumor-initiating cellschemoresistancedocetaxelpdx (patient-derived orthoxenografts)triple negative breast cancer (tnbc) |
| spellingShingle | Jorge Gomez-Miragaya Eva González-Suárez Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer Molecular & Cellular Oncology cd49f tumor-initiating cells chemoresistance docetaxel pdx (patient-derived orthoxenografts) triple negative breast cancer (tnbc) |
| title | Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer |
| title_full | Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer |
| title_fullStr | Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer |
| title_full_unstemmed | Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer |
| title_short | Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer |
| title_sort | tumor initiating cd49f cells are a hallmark of chemoresistant triple negative breast cancer |
| topic | cd49f tumor-initiating cells chemoresistance docetaxel pdx (patient-derived orthoxenografts) triple negative breast cancer (tnbc) |
| url | http://dx.doi.org/10.1080/23723556.2017.1338208 |
| work_keys_str_mv | AT jorgegomezmiragaya tumorinitiatingcd49fcellsareahallmarkofchemoresistanttriplenegativebreastcancer AT evagonzalezsuarez tumorinitiatingcd49fcellsareahallmarkofchemoresistanttriplenegativebreastcancer |